Lin S, Luo S, Gu D, Li M, et al. First-line durvalumab in addition to etoposide and platinum for extensive-stage small cell lung cancer: a United States-based cost-effectiveness analysis. Oncologist 2021 Aug 25. doi: 10.1002/onco.13954.
PMID: 34431578